Literature DB >> 3087582

Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs.

R M Ridley, T K Murray, J A Johnson, H F Baker.   

Abstract

Five common marmosets (Callithrix jacchus) received unilateral ibotenic acid lesions of the basal nucleus of Meynert (nBM). Seven days later, choline acetyltransferase activity was significantly reduced by 50% in the frontal and temporal neocortex, 40% in the amygdala, and approximately 30% in the motor, parietal and occipital cortex in the ipsilateral hemisphere. Four marmosets receiving equivalent bilateral ibotenic acid lesions were severely impaired on new visual object discrimination learning and on relearning an object discrimination learnt prior to surgery when compared with operated controls. New learning in lesioned animals was substantially improved by i.m. administration of the cholinergic agonist arecoline. Lesioned animals' learning ability improved with time but these animals were then differentially sensitive to the disruptive effect of scopolamine on discrimination learning. These results show that lesions of the nBM which destroy the rising cholinergic pathways impair learning ability but that this ability can be substantially restored by administration of a cholinergic agonist.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087582     DOI: 10.1016/0006-8993(86)90904-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

Review 1.  Ion channel genes and human neurological disease: recent progress, prospects, and challenges.

Authors:  E C Cooper; L Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Nerve growth factor differentially affects spatial and recognition memory in aged rats.

Authors:  G Niewiadomska; M Baksalerska-Pazera; A Gasiorowska; A Mietelska
Journal:  Neurochem Res       Date:  2006-11-17       Impact factor: 3.996

Review 3.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification.

Authors:  M Sarter; J P Bruno; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

6.  Basal nucleus lesions in monkeys: recognition memory impairment or visual agnosia?

Authors:  R M Ridley; H F Baker; T K Murray
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.

Authors:  T T Soncrant; K C Raffaele; S Asthana; A Berardi; P P Morris; J V Haxby
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.

Authors:  J J Hagan; J H Jansen; F E Nefkens; T de Boer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.

Authors:  H F Baker; R M Ridley; L W Duchen; T J Crow; C J Bruton
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

10.  Cholinergic neural transplants into hippocampus restore learning ability in monkeys with fornix transections.

Authors:  R M Ridley; H D Thornley; H F Baker; A Fine
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.